Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

693 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Metabolomic/lipidomic profiling of COVID-19 and individual response to tocilizumab.
Meoni G, Ghini V, Maggi L, Vignoli A, Mazzoni A, Salvati L, Capone M, Vanni A, Tenori L, Fontanari P, Lavorini F, Peris A, Bartoloni A, Liotta F, Cosmi L, Luchinat C, Annunziato F, Turano P. Meoni G, et al. Among authors: mazzoni a. PLoS Pathog. 2021 Feb 1;17(2):e1009243. doi: 10.1371/journal.ppat.1009243. eCollection 2021 Feb. PLoS Pathog. 2021. PMID: 33524041 Free PMC article.
Pulmonary vascular improvement in severe COVID-19 patients treated with tocilizumab.
Salvati L, Occhipinti M, Gori L, Ciani L, Mazzoni A, Maggi L, Capone M, Parronchi P, Liotta F, Miele V, Annunziato F, Lavorini F, Cosmi L. Salvati L, et al. Among authors: mazzoni a. Immunol Lett. 2020 Dec;228:122-128. doi: 10.1016/j.imlet.2020.10.009. Epub 2020 Nov 5. Immunol Lett. 2020. PMID: 33161002 Free PMC article.
Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent.
Mazzoni A, Salvati L, Maggi L, Capone M, Vanni A, Spinicci M, Mencarini J, Caporale R, Peruzzi B, Antonelli A, Trotta M, Zammarchi L, Ciani L, Gori L, Lazzeri C, Matucci A, Vultaggio A, Rossi O, Almerigogna F, Parronchi P, Fontanari P, Lavorini F, Peris A, Rossolini GM, Bartoloni A, Romagnani S, Liotta F, Annunziato F, Cosmi L. Mazzoni A, et al. J Clin Invest. 2020 Sep 1;130(9):4694-4703. doi: 10.1172/JCI138554. J Clin Invest. 2020. PMID: 32463803 Free PMC article.
Prompt Predicting of Early Clinical Deterioration of Moderate-to-Severe COVID-19 Patients: Usefulness of a Combined Score Using IL-6 in a Preliminary Study.
Vultaggio A, Vivarelli E, Virgili G, Lucenteforte E, Bartoloni A, Nozzoli C, Morettini A, Berni A, Malandrino D, Rossi O, Nencini F, Pieralli F, Peris A, Lagi F, Scocchera G, Spinicci M, Trotta M, Mazzetti M, Parronchi P, Cosmi L, Liotta F, Fontanari P, Mazzoni A, Salvati L, Maggi E, Annunziato F, Almerigogna F, Matucci A. Vultaggio A, et al. Among authors: mazzoni a. J Allergy Clin Immunol Pract. 2020 Sep;8(8):2575-2581.e2. doi: 10.1016/j.jaip.2020.06.013. Epub 2020 Jun 19. J Allergy Clin Immunol Pract. 2020. PMID: 32565226 Free PMC article.
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study.
Vannucchi AM, Sordi B, Morettini A, Nozzoli C, Poggesi L, Pieralli F, Bartoloni A, Atanasio A, Miselli F, Paoli C, Loscocco GG, Fanelli A, Para O, Berni A, Tassinari I, Zammarchi L, Maggi L, Mazzoni A, Scotti V, Falchetti G, Malandrino D, Luise F, Millotti G, Bencini S, Capone M, Piccinni MP, Annunziato F, Guglielmelli P; RUXO-COVID Study Group. Vannucchi AM, et al. Among authors: mazzoni a. Leukemia. 2021 Apr;35(4):1121-1133. doi: 10.1038/s41375-020-01018-y. Epub 2020 Aug 19. Leukemia. 2021. PMID: 32814839 Free PMC article. Clinical Trial.
Quantitative and qualitative alterations of circulating myeloid cells and plasmacytoid DC in SARS-CoV-2 infection.
Peruzzi B, Bencini S, Capone M, Mazzoni A, Maggi L, Salvati L, Vanni A, Orazzini C, Nozzoli C, Morettini A, Poggesi L, Pieralli F, Peris A, Bartoloni A, Vannucchi AM, Liotta F, Caporale R, Cosmi L, Annunziato F. Peruzzi B, et al. Among authors: mazzoni a. Immunology. 2020 Dec;161(4):345-353. doi: 10.1111/imm.13254. Epub 2020 Oct 6. Immunology. 2020. PMID: 32870529 Free PMC article.
Cell-mediated and humoral adaptive immune responses to SARS-CoV-2 are lower in asymptomatic than symptomatic COVID-19 patients.
Mazzoni A, Maggi L, Capone M, Spinicci M, Salvati L, Colao MG, Vanni A, Kiros ST, Mencarini J, Zammarchi L, Mantengoli E, Menicacci L, Caldini E, Romagnani S, Liotta F, Morettini A, Rossolini GM, Bartoloni A, Cosmi L, Annunziato F. Mazzoni A, et al. Eur J Immunol. 2020 Dec;50(12):2013-2024. doi: 10.1002/eji.202048915. Epub 2020 Nov 9. Eur J Immunol. 2020. PMID: 33080068 Free article. Clinical Trial.
First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19.
Mazzoni A, Di Lauria N, Maggi L, Salvati L, Vanni A, Capone M, Lamacchia G, Mantengoli E, Spinicci M, Zammarchi L, Kiros ST, Rocca A, Lagi F, Colao MG, Parronchi P, Scaletti C, Turco L, Liotta F, Rossolini GM, Cosmi L, Bartoloni A, Annunziato F; COVID-19 Research Group. Mazzoni A, et al. J Clin Invest. 2021 Jun 15;131(12):e149150. doi: 10.1172/JCI149150. J Clin Invest. 2021. PMID: 33939647 Free PMC article.
Impaired response to first SARS-CoV-2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib.
Guglielmelli P, Mazzoni A, Maggi L, Kiros ST, Zammarchi L, Pilerci S, Rocca A, Spinicci M, Borella M, Bartoloni A, Rossolini GM, Annunziato F, Vannucchi AM. Guglielmelli P, et al. Among authors: mazzoni a. Am J Hematol. 2021 Nov 1;96(11):E408-E410. doi: 10.1002/ajh.26305. Epub 2021 Aug 12. Am J Hematol. 2021. PMID: 34331712 Free PMC article. No abstract available.
693 results